医院环境下艰难梭菌候选疫苗的有效性与成本效果
研究采用基于主体的模拟模型,在300张床位的医院中评估艰难梭菌候选疫苗针对高危患者接种的有效性与成本效果。假设疫苗效力60-90%,接种40%高危患者可减少症状性CDI 16.6%(95%CI:15.2,17.9),接种80%可减少34.6%(95%CI:33.7,35.9)。在支付意愿为1000加元时,40%覆盖下疫苗每人接种成本不超过111加元即具成本效果,80%覆盖下不超过121加元。
要点
- 接种40%高危患者可减少症状性CDI 16.6%(95%CI:15.2,17.9)。
- 接种80%高危患者可减少症状性CDI 34.6%(95%CI:33.7,35.9)。
- 支付意愿1000加元时,40%覆盖下每人接种成本≤111加元具成本效果。
核心结论
- 由于减少CDI相关隔离天数,高危患者接种疫苗在取决于支付意愿和每人接种成本的情况下可具成本效果。
- 约80%的医院定植由艰难梭菌环境传播引起,这显著降低了疫苗的有效性,使其低于假设效力。
研究设计与样本
- 研究开发了300张床位医院内医院获得性CDI的基于主体模拟模型。
- 以高危患者为疫苗接种目标,估算症状性CDI的减少量。
- 从医疗服务提供者视角,利用CDI相关隔离天数的净减少,在2年期间评估疫苗成本效果,接种前平均月发病率为每10,000患者日5例。
主要发现
- 假设疫苗效力在60-90%范围,入院前接种40%高危患者使症状性CDI减少16.6%(95%CI:15.2,17.9)。
- 疫苗覆盖率增至80%时,症状性CDI减少34.6%(95%CI:33.7,35.9)。
- 约80%的医院定植由艰难梭菌环境传播引起,显著降低疫苗有效性至低于假设效力。
关键数值与推荐
- 支付意愿为1000加元(相当于每日病例隔离的平均成本)时,40%疫苗覆盖场景下每人接种成本不超过111加元疫苗具成本效果。
- 相同支付意愿下,疫苗覆盖率增至80%时,每人接种成本不超过121加元疫苗具成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Toxoid vaccines against Clostridium difficile infections (CDI) appear promising in reducing the risk of developing toxin-mediated symptoms. We sought to evaluate the effectiveness and cost-effectiveness of a vaccine candidate in a hospital setting. We developed an agent-based simulation model of nosocomial CDI in a 300-bed hospital. Targeting high-risk patients for vaccination, we estimated the reduction of symptomatic CDI. Using the net reduction of CDI-associated isolation days, we evaluated the vaccine's cost-effectiveness from a healthcare provider perspective over a 2-year period with an average monthly incidence of 5 cases per 10,000 patient-days pre-vaccination. Assuming a vaccine efficacy in the range 60-90%, vaccinating 40% of high-risk patients pre-admission reduced symptomatic CDI by 16.6% (95% CI: 15.2, 17.9). When the vaccine coverage increased to 80%, the reduction of symptomatic CDI was 34.6% (95% CI: 33.7, 35.9). For a willingness to pay (WTP) of CDN$1000 (corresponding to the average costs of case isolation per day), vaccine was cost-effective for vaccination costs per individual (VCPI) up to CDN$111 in the scenario of 40% vaccine coverage. With the same WTP, vaccine was cost-effective for VCPI up to CDN$121 when the vaccine coverage increased to 80%. A significant portion (~80%) of hospital colonization is caused by environmental transmission of C. difficile, which markedly reduced the effectiveness of vaccine below its assumed efficacy. However, due to the number of CDI-associated isolation days averted, vaccination of high-risk patients can be cost-effective depending on the WTP and the VCPI.
引用
- Champredon D, Shoukat A, Moghadas SM, et al. Effectiveness and cost-effectiveness of a Clostridium difficile vaccine candidate in a hospital setting. Vaccine. 2020. PMID: 32014268. doi:10.1016/j.vaccine.2020.01.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。